Preparation and characterization of niosomes containing ribavirin for liver targeting

References

• Alving, C.R. (1983). Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther. 22:407–24.
   PubMed Web of Science ®Google Scholar
• Alving, C.R., Steck, E.A., Chapman, W.L., Waits, V.B., Hendricks, L.G., Swartz, G.M., Hanson, W.L. (1978). Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci USA. 75:2959–63.
   PubMed Web of Science ®Google Scholar
• Antonio, D., Avolio, A.I., Mauro, S., Marco, S., Daniel Gonzalez de Requena, S.B., Giovanni, D.P. (2006). Validation of Liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatography B. 835:127–30.
   PubMed Web of Science ®Google Scholar
• Arunothayanun, P., Bernard, M.S., Craig, D.M., Uchegbu, I.F., Florence, A.T. (2000). The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from hexadecyl diglycerol ether. Int J Pharm. 201:7–14.
   PubMed Web of Science ®Google Scholar
• Arunothayanun, P., Turton, J.A., Uchegbu, I.F., Florence, A.T. (1999). Preparation and in vitro/ in vivo evaluation of leutenizing hormone releasing hormone (LHRH)-loaded polyhederal and spherical/tubular niosomes. J Pharm Sci. 88:34–8.
   PubMed Web of Science ®Google Scholar
• Azmin, M.N, Florence, A.T., Handjani-Vila, R.M., Stuart, J.B., Van-lerberghe, G., Whittaker, J.S. (1985). The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol. 37:237–42.
   PubMed Web of Science ®Google Scholar
• Baillie, A.J., Florence, A.T., Hume, L.R., Muirhead, G.T., Rogerson, A. (1985). The preparation and properties of niosomes non-ionic surfactant vesicles. J Pharm Pharmacol. 37:863–8.
   PubMed Web of Science ®Google Scholar
• Bhavana, V., Ajay, J.K., Jain, N.K. (1998). Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Contr Rel. 54:149–65.
   PubMed Web of Science ®Google Scholar
• Biju, S.S., Talegaonkar, S., Misra, P.R., Khar, R.K. (2006). Vesicular systems: an overview. Indian J Pharm Sci. 68:141–53.
   Google Scholar
• Cable, C. (1989). An examination of the effects of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles. PhD Thesis, University of Strathclyde, Glasgow, UK.
   Google Scholar
• Carafa, M., Santucci, E., Alhaique, F., Coviello, T., Murtas, E., Riccieri, F.M., Lucania, G., Torrisi, M.R. (1998). Preparation and properties of new unilamellar nonionic/ionic surfactant vesicles. Int J Pharm. 160:51–9.
   Web of Science ®Google Scholar
• Chandraprakash, K.S, Udupa, N., Umadevi, P., Pillai, G.K. (1990). Pharmacokinetic evaluation of surfactant vesicle-entrapped methotrexate in tumor-bearing mice. Int J Pharmacokinet. 61:R1–3.
   Web of Science ®Google Scholar
• Chen-Chung, L., Li-Tain, Y., Trong, L., David, L., Johnson, Y.L. (2003). Pharmacokinetics and metabolism of 14 C ribavirin in rats and cyanomolgus monkeys. Antimicrob Agents Chemother. 47:1395–8.
   PubMed Web of Science ®Google Scholar
• Deepika, A., Indu, P.K. (2005). Improved pharmacodynamics of timolol maleate from mucoahesive niosomal ophthalmic drug delivery system. Int J Pharm. 290:155–9.
   PubMed Web of Science ®Google Scholar
• Gianasi, E., Cociancich, F., Uchegbu, I.F., Florence, A.T., Duncan, R. (1997). Pharmaceutical and biological characterization of a doxorubicin-polymer conjugate (PK1) entrapped in sorbitan monostearate Span 60 niosomes. Int J Pharm. 148:139–48.
   Web of Science ®Google Scholar
• Hunter, C.A., Dolan, T..F., Coombs, G.H., Baillie, A.J. (1988). Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral Leischmaniasis. J Pharm Pharmacol. 40:161–5.
   PubMed Web of Science ®Google Scholar
• Ijeoma, F.U., Vyas S.P. (1998). Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 172:33–70.
   Web of Science ®Google Scholar
• Jen, J.F., Glue, P., Gupta, S., Zambas, D., Hajian, G. (2000). Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 22:555–65.
   PubMed Web of Science ®Google Scholar
• Kaur, I.P., Kanwar, M. (2002). Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 28:473–93.
   PubMed Web of Science ®Google Scholar
• Larrat, S., Stanke-Labesque, F., Plages, A., Zarski, J.P., Bessard, G., Souvignet, C. (2003). Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 47:124–9.
   PubMed Web of Science ®Google Scholar
• Laskus, T., Radkowski, M., Piasek, A. (2000). Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis. 181:442–8.
   PubMed Web of Science ®Google Scholar
• Lindahl, K., Stahle, L., Bruchfeld, A., Schvarcz, R. (2005). High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 41:275–9.
   PubMed Web of Science ®Google Scholar
• Li-Tain, Y., Mai, N., Sohelia, D., Wei, B., Chin-chung, L. (2007). LC-MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells. J Pharm Biomed Anal. 43:1057–64.
   PubMed Web of Science ®Google Scholar
• Marek, R., Agnieszka, B., Andrzej, H., Janusz, S., Jeffrey, W., Debra, M., Marek, N.R., Tomasz, L. (2004). Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-a and interleukin 8. J Gen Virol. 85:47–59.
   PubMed Web of Science ®Google Scholar
• McIntosh, T.J. (1978). The effect of cholesterol content on the structure of phosphatidylcholine bilayers. Biochim Biophys Acta. 51:43–58.
   Web of Science ®Google Scholar
• Meir, K., Carl, R.A., Wayne, L.R., Glenn, M., Swartz, J.R., Peter, G.C. (1985). Enhanced efficacy of liposome-Encapsulated ribavirin against rift valley fever virus infection in mice. Antimicrob Agents Chemother. 27:903–7.
   PubMed Web of Science ®Google Scholar
• Mitra, A.K. (2003). Ophthalmic drug delivery systems. 2nd ed. Mitra, A.K., ed. Drugs and the Pharmaceutical Sciences. New York: Marcel Dekker, Vol. 130.
   Google Scholar
• Patterson, J.L., Fernandez-Larsson, R. (1990). Molecular mechanisms of action of ribavirin. Rev Infect Dis. 12:1139–46.
   PubMedGoogle Scholar
• Raja, N.A., Singti, U.V., Udupa, N., Pillai, G.K. (1993). Anti-inflammatory activity of niosome encapsulated diclofenac sodium in rats. Indian Drugs. 30:275–8.
   Google Scholar
• Raymond, M., Josbert, M., Marcel, H., Adrienne, P., Grietje, M., Gert, S. (2005). Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia. 7:118–27.
   PubMed Web of Science ®Google Scholar
• Rogerson, A., Cummings, J., Florence, A.T. (1987). Adriamycin loaded niosomes: drug entrapment, stability and release. J Microencapsulation. 4:321–8.
   PubMed Web of Science ®Google Scholar
• Rogerson, A., Cummings, J., Willmott, N., Florence, A.T. (1988). The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol. 40:337–42.
   PubMed Web of Science ®Google Scholar
• Schreier, H., Bouwstra, J. (1994). Liposomes and niosomes as topical drug carrier: dermal and transdermal drug delivery. J Contr Rel. 30:1–15.
   Web of Science ®Google Scholar
• Strader, D.B., Wright, T., Thomas, D.L., Seeff, L.B. (2004). Diagnosis, management and treatment of hepatitis C. Hepatology. 39:1147–71.
   PubMed Web of Science ®Google Scholar
• Yoshioka, T., Florence, A.T. (1994). Vesicle (niosome)-in-water-in-oil (v:w:o) emulsions—an in-vitro study. Int J Pharm. 108:117–23.
   Web of Science ®Google Scholar